PHIO

Phio Pharmaceuticals Corp. (PHIO) | Rumor.io

Phio Pharmaceuticals

PHIO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,370

Bullish sentiment (50-day avg)86%

Price to earnings ratio0.01

Market capitalization11.7M

Earnings per share-1.29

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8.7M

Social

What share of all stock conversation is about PHIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 19

Phio Pharmaceuticals Corp. (PHIO) is developing an RNAi cancer immunotherapy and has a tiny valuation of around $1 despite being in phase 1 trials.
PHIO's market cap is around 13m$, with a decent capital structure, and its RNAi cancer immunotherapy has the potential to silence PD1, a key target in cancer treatment.
The company is preparing for FDA approval, which is considered good news, and its CEO, Bitterman Robert J, has recently purchased 10,000 shares at $1.06.

Generated by AI

Sentiment

Of the messages about PHIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	83.33% -16.67	81.6% +0.51
Bearish	0%	0%	16.67% +16.67	18.4% -0.51

Bullish· Feb 13

$PHIO has the potential to reach $1.70-$1.85 as it tests new highs.
Institutional buying has increased, with heavy buying at $1.12 and potential for further growth.
The company's lead program, PH-762, has shown positive results in a skin cancer Phase 1b trial, with a potential catalyst for a price increase.

Bearish· Feb 10

$PHIO is predicted to fall to $10 due to 50% shorting on the dark pool.
The company's financial situation is dire, with negative 5 months of cash reserves, according to the SEC.
$PHIO has a 88.9% fail rate on its gaps, with a recent closing 20% below its open price, indicating potential further downside.

Generated by AI

Topics

Of the messages about PHIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	98.92%	67.46%
Technical Analysis	—	0%	0%	21.77%
Analysts	—	0%	0%	10.42%
Controversies	—	0%	1.08%	0.22%
Earnings	—	0%	0%	0.07%
Macro	—	0%	0%	0.07%

Announcements· Feb 10

Phio Pharmaceuticals Corp. ($PHIO) announced a positive review from the Safety Monitoring Committee (SMC) for its lead clinical candidate PH-762 in a skin cancer trial.
The SMC's review of the Phase 1b clinical trial for PH-762 showed an 85% tumor response in patients treated with the compound.
The news led to a significant surge in Phio's stock price, with shares increasing by 51.1% pre-market.

Technical Analysis· Feb 10

$PHIO has been forming higher lows and higher highs, with a VWAP hold at $1.35.
Price needs to hold above $1.24 to retain a bullish structure, with resistance levels at $1.15 (50ema/daily) and $1.36 (90 ema/daily).
The stock has a 88.9% fail rate on its last 10 gaps, with a potential zombie hour recovery and squeeze.

Generated by AI

Community

Of the messages about PHIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	40%	87.5%	89.83%	47.36%
Newcomers	60%	12.5%	10.17%	52.64%

Regulars· Feb 10

$PHIO is forming a bullish structure, with price holding above $1.24, and a 20% trade is possible if price can break through $1.45.
The Safety Monitoring Committee (SMC) has completed a planned safety review for all patients treated with INTASYL compound PH-762 in Phase 1b clinical trials for $PHIO, which is a positive development.
$PHIO is a strong candidate for a 30% move, with the next level set at $1.65, and $1.22 acting as support, based on the stock's recent price action.

Newcomers· Feb 15

The company's stock price has increased significantly, with a current price of $1.61 and a potential to reach $2.00, $2.20, $2.40, or $2.70.
Phio Pharmaceuticals Corp. has seen a surge in value after successful clinical trials for skin cancer treatment, with its market value reaching $35 million.
The stock has broken through key resistance levels and is expected to potentially make a big move, with one analyst targeting a specific price for the day.

Generated by AI

Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b TrialKing of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and...

16d agoYahoo Finance

Phio Pharmaceuticals director Plott buys $17,100 in shares

1mo agoInvesting.com

Phio Pharmaceuticals receives U.S. patent allowance for PH-894

1mo agoInvesting.com

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the...

1mo agoYahoo Finance

Also Discussed

Investors talking about PHIO also mention

#	Name	Attention
1	iShares Global Consumer Discretionary ETFRXI	0%0
2	Plus Therapeutics IncPSTV	0%0
3	YTEN - Yield10 Bioscience, Inc.	——
4	LIPO - Lipella Pharmaceuticals Inc.	——
5	XOMA CorporationXOMA	0%0
6	Opus Genetics Inc.OCUP	0%0
7	PFIN - P&F Industries, Inc.	——
8	SINTX Technologies, Inc. Common StockSINT	0%0
9	RGLS - Regulus Therapeutics Inc.	——
10	NLTX - Neoleukin Therapeutics, Inc.	——

Phio Pharmaceuticals Corp.

Healthcare
Biotechnology

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL RNA interference platform. The company’s current work centers on gene-silencing candidates designed to help immune cells better recognize and attack tumor cells, with a primary emphasis on cancer research and treatment applications. Its lead programs include PH-762, which targets PD-1 expression in ongoing clinical studies, and PH-894, which is being evaluated in preclinical research for selective BRD4 silencing. Phio Pharmaceuticals Corp. operates in the biotechnology sector and plays a role in advancing RNAi-based approaches for oncology, particularly in areas such as skin cancers and other solid tumors.

Website

Location

411 Swedeland Road

King of Prussia, PA, 19406

United States

Social

What share of all stock conversation is about PHIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Aug 19

Phio Pharmaceuticals Corp. (PHIO) is developing an RNAi cancer immunotherapy and has a tiny valuation of around $1 despite being in phase 1 trials.
PHIO's market cap is around 13m$, with a decent capital structure, and its RNAi cancer immunotherapy has the potential to silence PD1, a key target in cancer treatment.
The company is preparing for FDA approval, which is considered good news, and its CEO, Bitterman Robert J, has recently purchased 10,000 shares at $1.06.

Generated by AI

Sentiment

Of the messages about PHIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	83.33% -16.67	81.6% +0.51
Bearish	0%	0%	16.67% +16.67	18.4% -0.51

Bullish· Feb 13

$PHIO has the potential to reach $1.70-$1.85 as it tests new highs.
Institutional buying has increased, with heavy buying at $1.12 and potential for further growth.
The company's lead program, PH-762, has shown positive results in a skin cancer Phase 1b trial, with a potential catalyst for a price increase.

Bearish· Feb 10

$PHIO is predicted to fall to $10 due to 50% shorting on the dark pool.
The company's financial situation is dire, with negative 5 months of cash reserves, according to the SEC.
$PHIO has a 88.9% fail rate on its gaps, with a recent closing 20% below its open price, indicating potential further downside.

Generated by AI

Topics

Of the messages about PHIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	98.92%	67.46%
Technical Analysis	—	0%	0%	21.77%
Analysts	—	0%	0%	10.42%
Controversies	—	0%	1.08%	0.22%
Earnings	—	0%	0%	0.07%
Macro	—	0%	0%	0.07%

Announcements· Feb 10

Phio Pharmaceuticals Corp. ($PHIO) announced a positive review from the Safety Monitoring Committee (SMC) for its lead clinical candidate PH-762 in a skin cancer trial.
The SMC's review of the Phase 1b clinical trial for PH-762 showed an 85% tumor response in patients treated with the compound.
The news led to a significant surge in Phio's stock price, with shares increasing by 51.1% pre-market.

Technical Analysis· Feb 10

$PHIO has been forming higher lows and higher highs, with a VWAP hold at $1.35.
Price needs to hold above $1.24 to retain a bullish structure, with resistance levels at $1.15 (50ema/daily) and $1.36 (90 ema/daily).
The stock has a 88.9% fail rate on its last 10 gaps, with a potential zombie hour recovery and squeeze.

Generated by AI

Community

Of the messages about PHIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	40%	87.5%	89.83%	47.36%
Newcomers	60%	12.5%	10.17%	52.64%

Regulars· Feb 10

$PHIO is forming a bullish structure, with price holding above $1.24, and a 20% trade is possible if price can break through $1.45.
The Safety Monitoring Committee (SMC) has completed a planned safety review for all patients treated with INTASYL compound PH-762 in Phase 1b clinical trials for $PHIO, which is a positive development.
$PHIO is a strong candidate for a 30% move, with the next level set at $1.65, and $1.22 acting as support, based on the stock's recent price action.

Newcomers· Feb 15

The company's stock price has increased significantly, with a current price of $1.61 and a potential to reach $2.00, $2.20, $2.40, or $2.70.
Phio Pharmaceuticals Corp. has seen a surge in value after successful clinical trials for skin cancer treatment, with its market value reaching $35 million.
The stock has broken through key resistance levels and is expected to potentially make a big move, with one analyst targeting a specific price for the day.

Generated by AI

Phio Pharmaceuticals

Social

Aug 19

Bullish· Feb 13

Bearish· Feb 10

Announcements· Feb 10

Technical Analysis· Feb 10

Regulars· Feb 10

Newcomers· Feb 15

Phio Announces Key PH-762 Milestone with FDA Submission for Next Stage of Cutaneous Squamous Cell Carcino

Phio Pharmaceuticals submits FDA briefing for PH-762 study

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals director Plott buys $17,100 in shares

Phio Pharmaceuticals receives U.S. patent allowance for PH-894

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

Also Discussed

Phio Pharmaceuticals Corp.

Company Information

Location

Phio Announces Key PH-762 Milestone with FDA Submission for Next Stage of Cutaneous Squamous Cell Carcino

Phio Pharmaceuticals submits FDA briefing for PH-762 study

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals director Plott buys $17,100 in shares

Phio Pharmaceuticals receives U.S. patent allowance for PH-894

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

Also Discussed

Social

Aug 19

Bullish· Feb 13

Bearish· Feb 10

Announcements· Feb 10

Technical Analysis· Feb 10

Regulars· Feb 10

Newcomers· Feb 15